GRIFOLS, S.A. - AMERICAN DEPOSITARY SHARES
Depository Receipt · US3984384087 · GRFS · A1J1E2 (XNAS)
8,99 USD
12.06.2025 20:38
Current Prices from GRIFOLS, S.A. - AMERICAN DEPOSITARY SHARES
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
GRFS
|
USD
|
12.06.2025 20:38
|
8,99 USD
| 8,95 USD
+0,45 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | 1,93 % | 16,30 % | 15,85 % | 18,29 % | 27,88 % | -53,23 % |
Company Profile for GRIFOLS, S.A. - AMERICAN DEPOSITARY SHARES Depository Receipt
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Invested Funds
The following funds have invested in: GRIFOLS, S.A. - AMERICAN DEPOSITARY SHARES invested:
Fund | Vol. in million 58,85 | Percentage (%) 0,14 % |
Company Data
Name GRIFOLS, S.A. - AMERICAN DEPOSITARY SHARES
Company Grifols, S.A.
Symbol GRFS
Website
https://www.grifols.com
Primary Exchange
NASDAQ

WKN A1J1E2
ISIN US3984384087
Asset Class Depository Receipt
Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Jose Ignacio Abia Buenache
Market Capitalization 6 Mrd.
Country Spain
Currency USD
Employees 23,8 T
Address Avinguda de la Generalitat, 152, 08174 Barcelona
IPO Date 2011-06-02
Stock Splits
Date | Split |
---|---|
04.01.2016 | 2:1 |
11.12.2012 | 21:20 |
23.07.2012 | 1:2 |
01.12.2011 | 11:10 |
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | G0FB.F |
NASDAQ | GRFS |
More Shares
Investors who GRIFOLS, S.A. - AMERICAN DEPOSITARY SHARES hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.